These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28662222)

  • 1. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
    Esserman LJ; Yau C; Thompson CK; van 't Veer LJ; Borowsky AD; Hoadley KA; Tobin NP; Nordenskjöld B; Fornander T; Stål O; Benz CC; Lindström LS
    JAMA Oncol; 2017 Nov; 3(11):1503-1510. PubMed ID: 28662222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
    Opdam M; van der Noort V; Kleijn M; Glas A; Mandjes I; Kleiterp S; Hilbers FS; Kruger DT; Bins AD; de Jong PC; Schiphorst PPJBM; van Dalen T; Flameling B; Rietbroek RC; Beeker A; van den Heiligenberg SM; Bakker SD; Wymenga ANM; Oving IM; Bijlsma RM; van Diest PJ; Vermorken JB; van Tinteren H; Linn SC
    Breast Cancer Res Treat; 2022 Jul; 194(2):265-278. PubMed ID: 35587322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
    Albain KS; Barlow WE; Shak S; Hortobagyi GN; Livingston RB; Yeh IT; Ravdin P; Bugarini R; Baehner FL; Davidson NE; Sledge GW; Winer EP; Hudis C; Ingle JN; Perez EA; Pritchard KI; Shepherd L; Gralow JR; Yoshizawa C; Allred DC; Osborne CK; Hayes DF;
    Lancet Oncol; 2010 Jan; 11(1):55-65. PubMed ID: 20005174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
    Hughes KS; Schnaper LA; Bellon JR; Cirrincione CT; Berry DA; McCormick B; Muss HB; Smith BL; Hudis CA; Winer EP; Wood WC
    J Clin Oncol; 2013 Jul; 31(19):2382-7. PubMed ID: 23690420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
    Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
    Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
    Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
    Esserman LJ; Moore DH; Tsing PJ; Chu PW; Yau C; Ozanne E; Chung RE; Tandon VJ; Park JW; Baehner FL; Kreps S; Tutt AN; Gillett CE; Benz CC
    Breast Cancer Res Treat; 2011 Sep; 129(2):607-16. PubMed ID: 21597921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
    JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
    Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
    JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
    Bedognetti D; Sertoli MR; Pronzato P; Del Mastro L; Venturini M; Taveggia P; Zanardi E; Siffredi G; Pastorino S; Queirolo P; Gardin G; Wang E; Monzeglio C; Boccardo F; Bruzzi P
    J Natl Cancer Inst; 2011 Oct; 103(20):1529-39. PubMed ID: 21921285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
    Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
    J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant radiation therapy alone is associated with improved overall survival compared to hormonal therapy alone in older women with estrogen receptor positive early stage breast cancer.
    Jhawar SR; Alpert N; Taioli E; Sayan M; Bazan J; Park KU; Stover D; Cherian M; White J; Haffty B; Ohri N
    Cancer Med; 2020 Nov; 9(22):8345-8354. PubMed ID: 32942344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
    Fitzal F; Filipits M; Fesl C; Rudas M; Greil R; Balic M; Moinfar F; Herz W; Dubsky P; Bartsch R; Ferree S; Schaper C; Gnant M;
    Br J Surg; 2021 Apr; 108(3):308-314. PubMed ID: 33608712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic index of sensitivity to endocrine therapy for breast cancer.
    Symmans WF; Hatzis C; Sotiriou C; Andre F; Peintinger F; Regitnig P; Daxenbichler G; Desmedt C; Domont J; Marth C; Delaloge S; Bauernhofer T; Valero V; Booser DJ; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2010 Sep; 28(27):4111-9. PubMed ID: 20697068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
    van 't Veer LJ; Yau C; Yu NY; Benz CC; Nordenskjöld B; Fornander T; Stål O; Esserman LJ; Lindström LS
    Breast Cancer Res Treat; 2017 Nov; 166(2):593-601. PubMed ID: 28776283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.